<DOC>
	<DOCNO>NCT02890511</DOCNO>
	<brief_summary>A study DHP107 , novel oral paclitaxel formulation , determine maximum tolerate dose recommend dose phase II trial patient advance solid cancer explore efficacy DHP107 patient gastric cancer</brief_summary>
	<brief_title>A Study DHP107 , Novel Oral Paclitaxel Formulation , Patients With Advanced Solid Tumours Gastric Cancer</brief_title>
	<detailed_description>1 . Primary objective To determine maximum tolerate dose recommend dose phase 2 clinical trial repeat administration DHP107 ( oral paclitaxel ) advance solid cancer patient 2 . Secondary objective - To identify dose limit toxicity safety ( toxicity ) DHP107 - To evaluate efficacy ( tumor response rate ) DHP107 - To assess pharmacokinetic ( PK ) characteristic DHP107</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patients 18 70 year old 2 . Patients prognosed advanced metastatic solid cancer histopathology cytology analysis available standard therapy fail least standard therapy 3 . Adequate bone marrow function , liver function adequate kidney function 4 . Eastern Cooperative Oncology Group performance status â‰¤ 2 5 . Life expectancy 3 month 6 . Written inform consent 1 . Major infectious neurological disease bowel obstruction 2 . Brain metastasis hematologic malignancy 3 . Patients underwent surgery , radiation therapy , hormone chemotherapy within 4 week prior begin investigational drug administration 4 . Patients history failure taxane line chemotherapy ( exception use 6 month adjuvant therapy treatment discontinue due docetaxel related side effect ) 5 . Patients require continuously take Pgp ( Pglycoprotein ) suppressor , immune suppressor , protonpump inhibitor H2receptor antagonist clinical trial period 6 . Patients deem investigator suffer severe heart disease ( myocardial infarction , congestive heart failure , arrythmia accompany drastic change ECG , severe unstable angina pectoris , severe heart disease ) accompany severe internal disease ( uncontrollable diabetes , chronic obstructive pulmonary disease ) 7 . Patients prior history participate clinical trial within 30 day registration current clinical trial 8 . Patient history alcohol drug abuse recent 3 month 9 . Pregnant woman , nurse mother , patient childbearing age agree contraception ( men woman ) 10 . Patients ( suspect ) abnormality bile acid secretion ( e.g. , . patient resect gallbladder ) 11 . Patients history serious gastrointestinal bleeding , disease could affect absorption oral medication ( malabsorption syndrome , active peptic ulcer ) 12 . Patients history severe hypersensitive reaction active ingredient excipient investigational drug 13 . Patient state deem inappropriate participate clinical trial investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>